Juan A Sanchez-Arias
Overview
Explore the profile of Juan A Sanchez-Arias including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
264
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rabal O, Sanchez-Arias J, Cuadrado-Tejedor M, de Miguel I, Perez-Gonzalez M, Garcia-Barroso C, et al.
ACS Chem Neurosci
. 2019 Aug;
10(9):4076-4101.
PMID: 31441641
Here, we present a series of dual-target phosphodiesterase 9 (PDE9) and histone deacetylase (HDAC) inhibitors devised as pharmacological tool compounds for assessing the implications of these two targets in Alzheimer's...
2.
Cuadrado-Tejedor M, Perez-Gonzalez M, Garcia-Munoz C, Muruzabal D, Garcia-Barroso C, Rabal O, et al.
Front Aging Neurosci
. 2019 Jul;
11:149.
PMID: 31281249
The discouraging results with therapies for Alzheimer's disease (AD) in clinical trials, highlights the urgent need to adopt new approaches. Like other complex diseases, it is becoming clear that AD...
3.
Martinez-Pinilla E, Aguinaga D, Navarro G, Rico A, Oyarzabal J, Sanchez-Arias J, et al.
Mol Neurobiol
. 2019 Jan;
56(8):5900-5910.
PMID: 30687889
Cannabinoid CB receptors (CBR) and the GPR55 receptor are expressed in striatum and are potential targets in the therapy of Parkinson's disease (PD), one of the most prevalent neurodegenerative diseases...
4.
Rabal O, Sanchez-Arias J, Cuadrado-Tejedor M, de Miguel I, Perez-Gonzalez M, Garcia-Barroso C, et al.
ACS Chem Neurosci
. 2018 Dec;
10(3):1765-1782.
PMID: 30525452
In order to determine the contributions of histone deacetylase (HDAC) isoforms to the beneficial effects of dual phosphodiesterase 5 (PDE5) and pan-HDAC inhibitors on in vivo models of Alzheimer's disease...
5.
Franco R, Sanchez-Arias J, Navarro G, Lanciego J
Front Neuroanat
. 2018 Jul;
12:52.
PMID: 30002620
Gaucher's disease (GD) is the most prevalent lysosomal storage disorder. GD is caused by homozygous mutations of the GBA1 gene, which codes for beta-glucocerebrosidase (GCase). Although GD primarily affects peripheral...
6.
de Miguel I, Orbe J, Sanchez-Arias J, Rodriguez J, Salicio A, Rabal O, et al.
ACS Med Chem Lett
. 2018 May;
9(5):428-433.
PMID: 29795754
In an effort to find novel chemical series as antifibrinolytic agents, we explore α-phenylsulfonyl-α-spiropiperidines bearing different zinc-binding groups (ZBGs) to target those metalloproteinases involved in the fibrinolytic process: MMP3 and...
7.
Rabal O, Sanchez-Arias J, Cuadrado-Tejedor M, de Miguel I, Perez-Gonzalez M, Garcia-Barroso C, et al.
Eur J Med Chem
. 2018 Mar;
150:506-524.
PMID: 29549837
We have identified chemical probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference versus class I HDACs) to decipher the contribution...
8.
Rodriguez J, Sobrino T, Lopez-Arias E, Ugarte A, Sanchez-Arias J, Vieites-Prado A, et al.
J Am Heart Assoc
. 2017 Jun;
6(6).
PMID: 28572282
Background: Intracerebral hemorrhage (ICH) is an acute neurological disorder with high mortality and no effective treatment. In addition to the initial bleeding event, rebleeding and hematoma expansion are associated with...
9.
Jose-Eneriz E, Agirre X, Rabal O, Vilas-Zornoza A, Sanchez-Arias J, Miranda E, et al.
Nat Commun
. 2017 May;
8:15424.
PMID: 28548080
The indisputable role of epigenetics in cancer and the fact that epigenetic alterations can be reversed have favoured development of epigenetic drugs. In this study, we design and synthesize potent...
10.
Sanchez-Arias J, Rabal O, Cuadrado-Tejedor M, de Miguel I, Perez-Gonzalez M, Ugarte A, et al.
ACS Chem Neurosci
. 2016 Dec;
8(3):638-661.
PMID: 27936591
A novel systems therapeutics approach, involving simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylase (HDAC), has been validated as a potentially novel therapeutic strategy for the treatment of Alzheimer's...